FOXL2
protein-codingforkhead box L2, the group of Forkhead boxes
Gene summary
This gene encodes a forkhead transcription factor. The protein contains a fork-head DNA-binding domain and may play a role in ovarian development and function. Expansion of a polyalanine repeat region and other mutations in this gene are a cause of blepharophimosis syndrome and premature ovarian failure 3. [provided by RefSeq, Jul 2016]
- BPES
MANE transcript
Inheritance
ClinVar variants
Top phenotype
gnomAD constraint
Max pathogenic AF
Genomic locus
External References & Databases
Transcript & Mutation Effects
hg38 • Region Span ~2.9 kbGenCC Phenotypes & Disease Associations
Curated gene-disease validity assertions and inheritance patterns
Inheritance Pattern: Unknown
Disease ID:MONDO:0012169
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0007201
Submitter: Labcorp Genetics (formerly Invitae)
Inheritance Pattern: AD
Disease ID:MONDO:0007201
Submitter: G2P
Inheritance Pattern: AD
Disease ID:MONDO:0007201
Submitter: PanelApp Australia
Inheritance Pattern: AD
Disease ID:MONDO:0007201
Submitter: Ambry Genetics
Clinical Genomic Database (CGD)
Manifestation: Craniofacial; Endocrine; Genitourinary; Obstetric; Ophthalmologic
Intervention: Obstetric
Rationale: Awareness may be beneficial to allow interventions such as preserving eggs in women with premature ovarian insufficiency (which is also reported in women with BPES)
ClinVar Associated Diseases & Phenotypes
Reported disease conditions connected to FOXL2 variants in ClinVar
ClinVar Variants & Pathogenicity by Type
Statistics based on transcript NM_023067.4. Only rare variants are included.
We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.
Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.
| Effect | PathogenicP | Likely pathogenicLP | VUS | Likely benignLB | BenignB | Sum |
|---|---|---|---|---|---|---|
| synonymous | 3 | 26 | 6 | 35 | ||
| missense | 9 | 32 | 92 | 3 | 1 | 137 |
| nonsense | 29 | 5 | 34 | |||
| start loss | 1 | 1 | ||||
| frameshift | 82 | 20 | 1 | 103 | ||
| splice donor/acceptor (+/-2bp) | 0 | |||||
| Total | 120 | 57 | 97 | 29 | 7 | 310 |
Highest pathogenic variant AF is 0.0001700949
Transcript Catalog
Annotated transcript isoforms across RefSeq and Ensembl databases
| Transcript ID | Source | Protein ID | Coding Exons | MANE Status |
|---|---|---|---|---|
| RefSeq | NP_075555.1 | 1 | MANE Select | |
| Ensembl | ENSP00000497217.1 | 1 | MANE Select |
Model Organisms & Knockout Phenotypes
Observed phenotypic effects in mouse and zebrafish models
| Gene / Model | Organism | Observed Phenotype |
|---|---|---|
| foxl2b | Danio rerio | Structure: oocyte Quality: increased occurrence abnormal |
Gene Ontology (GO) Annotations & Pathways
Biological processes, molecular functions, cellular components and pathways
Pathways ConsensusPathDB
- SUMOylation of transcription factors
- Post-translational protein modification
- SUMO E3 ligases SUMOylate target proteins
- Metabolism of proteins
- SUMOylation
Biological Process
- negative regulation of transcription by RNA polymerase II
- ovarian follicle development
- oocyte growth
- extraocular skeletal muscle development
- apoptotic DNA fragmentation
Molecular Function
- RNA polymerase II proximal promoter sequence-specific DNA binding
- DNA-binding transcription factor activity, RNA polymerase II-specific
- DNA-binding transcription activator activity, RNA polymerase II-specific
- DNA binding
- DNA-binding transcription factor activity
Cellular Component
- nucleus
- nucleoplasm
- intercellular bridge
gnomAD Constraint
Source:
- Gene type
- protein_coding
- Transcript type
- protein_coding
- Transcript
- ENST00000330315
- Coding exons
- 1
- Length
- 2917
- Individuals with no LoFs
- 0
- Homozygous LoFs
- 0
- Heterozygous LoFs
- 0
- Defined
- 0
- p
- 0.00
| Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible | |
|---|---|---|---|---|---|---|
| Missense | 1.76 | 109 | 175 | 0.624 | 0.00000801 | 2370 |
| Missense (PolyPhen) | 13 | 40.537 | 0.32069 | 468 | ||
| Synonymous | -0.521 | 84 | 78.1 | 1.07 | 0.00000390 | 822 |
| Loss of Function | 2.42 | 0 | 6.85 | 0.00 | 2.93e-7 | 90 |
Population LoF Frequency
| Population | CAF | p-value | Status |
|---|---|---|---|
| African | 0 | 0.0 | absent |
| Latino/Admixed American | 0 | 0.0 | absent |
| Ashkenazi Jewish | 0 | 0.0 | absent |
| East Asian | 0 | 0.0 | absent |
| Finnish | 0 | 0.0 | absent |
| European (Non-Finnish) | 0 | 0.0 | absent |
| South Asian | 0 | 0.0 | absent |
| Other | 0 | 0.0 | absent |
dbNSFP Gene Annotations
Source:
- Function
- FUNCTION: Transcriptional regulator. Critical factor essential for ovary differentiation and maintenance, and repression of the genetic program for somatic testis determination. Prevents trans- differentiation of ovary to testis through transcriptional repression of the Sertoli cell-promoting gene SOX9 (By similarity). Has apoptotic activity in ovarian cells. Suppresses ESR1-mediated transcription of PTGS2/COX2 stimulated by tamoxifen (By similarity). Is a regulator of CYP19 expression (By similarity). Participates in SMAD3-dependent transcription of FST via the intronic SMAD-binding element (By similarity). Is a transcriptional repressor of STAR. Activates SIRT1 transcription under cellular stress conditions. Activates transcription of OSR2. {ECO:0000250, ECO:0000269|PubMed:16153597, ECO:0000269|PubMed:19010791, ECO:0000269|PubMed:19429596, ECO:0000269|PubMed:19744555}.;
- Disease
- DISEASE: Blepharophimosis, ptosis, and epicanthus inversus syndrome (BPES) [MIM:110100]: A disorder characterized by eyelid dysplasia, small palpebral fissures, drooping eyelids and a skin fold curving in the mediolateral direction, inferior to the inner canthus. In type I BPSE (BPES1) eyelid abnormalities are associated with female infertility. Affected females show an ovarian deficit due to primary amenorrhea or to premature ovarian failure (POF). In type II BPSE (BPES2) affected individuals show only the eyelid defects. {ECO:0000269|PubMed:11175783, ECO:0000269|PubMed:11468277, ECO:0000269|PubMed:12400065, ECO:0000269|PubMed:12529855, ECO:0000269|PubMed:12630957, ECO:0000269|PubMed:12938087, ECO:0000269|PubMed:15257268, ECO:0000269|PubMed:16454982, ECO:0000269|PubMed:17089161, ECO:0000269|PubMed:18372316, ECO:0000269|PubMed:18484667, ECO:0000269|PubMed:18642388, ECO:0000269|Ref.2}. Note=The disease is caused by mutations affecting the gene represented in this entry. There is a mutational hotspot in the region coding for the poly-Ala domain, since 30% of all mutations in the ORF lead to poly-Ala expansions, resulting mainly in BPES type II.; DISEASE: Premature ovarian failure 3 (POF3) [MIM:608996]: An ovarian disorder defined as the cessation of ovarian function under the age of 40 years. It is characterized by oligomenorrhea or amenorrhea, in the presence of elevated levels of serum gonadotropins and low estradiol. {ECO:0000269|PubMed:12149404, ECO:0000269|PubMed:19429596}. Note=The disease is caused by mutations affecting the gene represented in this entry.;
Recessive Scores
- pRec
- 0.416
Essentials
- Essential (CRISPR)
- N
- Essential (CRISPR2)
- N
- Essential (gene trap)
- N
- Indispensability pred.
- E
- Indispensability score
- 0.953
Gene Damage Prediction
| All | Recessive | Dominant | |
|---|---|---|---|
| Mendelian | Medium | Medium | Medium |
| Primary Immunodeficiency | Medium | Medium | Medium |
| Cancer | Medium | Medium | Medium |